Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Table 3 Site of inflammation on abdominal computed tomography in the programmed cell death-1/programmed death-ligand 1 and cytotoxic T-lymphocyte antigen 4 groups

Site of inflammation	PD-1/PD-L1, n = 23	CTLA-4, n = 8
Jejunum, n (%)	1 (4.3)	2 (25.0)
Ileum, n (%)	2 (8.7)	2 (25.0)
Cecum, n (%)	2 (8.7)	2 (25.0)
Ascending colon, n (%)	3 (13.0)	4 (50.0)
Transverse colon, n (%)	3 (13.0)	3 (37.5)
Descending colon, n (%)	6 (26.1)	3 (37.5)
Sigmoid colon, n (%)	7 (30.4)	2 (25.0)
Rectum, n (%)	8 (34.8)	2 (25.0)
No findings, n (%)	9 (39.1)	2 (25.0)

CT: Computed tomography; CTLA-4: Cytotoxic T-lymphocyte antigen 4; PD-1/PD-L1: Programmed cell death-1/programmed death-ligand 1.